ECSP10010383A - Polvo para suspension oral de un macrolido inmunosupresor - Google Patents
Polvo para suspension oral de un macrolido inmunosupresorInfo
- Publication number
- ECSP10010383A ECSP10010383A ECSP10010383A ECSP10010383A EC SP10010383 A ECSP10010383 A EC SP10010383A EC SP10010383 A ECSP10010383 A EC SP10010383A EC SP10010383 A ECSP10010383 A EC SP10010383A
- Authority
- EC
- Ecuador
- Prior art keywords
- powder
- pharmaceutical compositions
- suspension
- oral suspension
- tacrolimus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion describe composiciones farmaceuticas que consisten en un polvo para suspension oral de tacrolimus que presenta gran estabilidad, como polvo para suspension y tambien una vez preparada la suspension extemporanea sin la formacion de aglomerados de tipo torta (cake), de buen sabor y agradable aroma. La invencion tambien describe el metodo de preparacion de las composiciones farmaceuticas, procedimiento en seco que consiste en mezclar durante un tiempo adecuado tacrolimus y los excipientes farmaceuticamente aceptables previamentetamizados, y el uso de las composiciones farmaceuticas para el tratamiento y prevencion del rechazo de transplante de organos y dermatitis atopica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2008000374A CL2008000374A1 (es) | 2008-02-05 | 2008-02-05 | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
PCT/IB2009/050455 WO2009098649A1 (es) | 2008-02-05 | 2009-02-05 | Polvo para suspensión oral de un macrólido inmunosupresor |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010383A true ECSP10010383A (es) | 2010-11-30 |
Family
ID=40261181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP10010383 ECSP10010383A (es) | 2008-02-05 | 2010-08-05 | Polvo para suspension oral de un macrolido inmunosupresor |
Country Status (15)
Country | Link |
---|---|
US (2) | US20110021553A1 (es) |
EP (1) | EP2248522B1 (es) |
JP (1) | JP2011511059A (es) |
CN (1) | CN101977602A (es) |
AR (1) | AR070323A1 (es) |
BR (1) | BRPI0908072A2 (es) |
CA (1) | CA2714237A1 (es) |
CL (1) | CL2008000374A1 (es) |
CO (1) | CO6660422A2 (es) |
EC (1) | ECSP10010383A (es) |
ES (1) | ES2355884B1 (es) |
MX (1) | MX349358B (es) |
PE (1) | PE20091372A1 (es) |
PT (1) | PT2248522T (es) |
WO (1) | WO2009098649A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN02850A (es) | 2011-10-31 | 2015-07-03 | Glaxosmithkline Intellectual Property Ltd | |
CN115804760A (zh) * | 2022-11-23 | 2023-03-17 | 无锡福祈制药有限公司 | 一种他克莫司纳米晶体胶囊剂及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
KR0177158B1 (ko) | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
ATE464900T1 (de) * | 1998-03-26 | 2010-05-15 | Astellas Pharma Inc | Retardpräparat mit makroliden wie tacrolimus |
DE602004028023D1 (de) | 2003-08-29 | 2010-08-19 | Lifecycle Pharma As | Tacrolimus enthaltende feste dispersionen |
ATE531368T1 (de) | 2003-08-29 | 2011-11-15 | Veloxis Pharmaceuticals As | Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung |
KR100866728B1 (ko) | 2004-11-12 | 2008-11-03 | 주식회사종근당 | 타크로리무스를 함유하는 주사제 |
EP1817315A1 (en) * | 2004-12-01 | 2007-08-15 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Processes for producing crystalline macrolides |
KR100678829B1 (ko) | 2004-12-06 | 2007-02-05 | 한미약품 주식회사 | 타크로리무스의 경구용 마이크로에멀젼 조성물 |
CA2590675A1 (en) | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
HUP0600097A3 (en) | 2006-02-08 | 2008-07-28 | Richter Gedeon Nyrt | Pharmaceutical compositions comprising tacrolimus and process for their preparation |
WO2008013416A1 (en) * | 2006-07-27 | 2008-01-31 | Amorepacific Corporation | Process for preparing powder comprising nanoparticles of sparingly soluble drug |
CN100515413C (zh) | 2006-09-15 | 2009-07-22 | 杭州平和安康医药科技有限公司 | 他克莫司口服制剂 |
-
2008
- 2008-02-05 CL CL2008000374A patent/CL2008000374A1/es unknown
-
2009
- 2009-01-29 AR ARP090100290 patent/AR070323A1/es unknown
- 2009-02-04 PE PE2009000163A patent/PE20091372A1/es not_active Application Discontinuation
- 2009-02-05 US US12/866,392 patent/US20110021553A1/en not_active Abandoned
- 2009-02-05 PT PT97087159T patent/PT2248522T/pt unknown
- 2009-02-05 MX MX2010008327A patent/MX349358B/es active IP Right Grant
- 2009-02-05 CN CN2009801101026A patent/CN101977602A/zh active Pending
- 2009-02-05 JP JP2010545589A patent/JP2011511059A/ja active Pending
- 2009-02-05 EP EP09708715.9A patent/EP2248522B1/en not_active Not-in-force
- 2009-02-05 BR BRPI0908072-4A patent/BRPI0908072A2/pt not_active Application Discontinuation
- 2009-02-05 CA CA 2714237 patent/CA2714237A1/en not_active Abandoned
- 2009-02-05 WO PCT/IB2009/050455 patent/WO2009098649A1/es active Application Filing
- 2009-02-05 ES ES201050015A patent/ES2355884B1/es not_active Expired - Fee Related
-
2010
- 2010-08-05 EC ECSP10010383 patent/ECSP10010383A/es unknown
- 2010-08-09 CO CO10097188A patent/CO6660422A2/es not_active Application Discontinuation
-
2013
- 2013-03-18 US US13/846,804 patent/US20140088135A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101977602A (zh) | 2011-02-16 |
EP2248522A1 (en) | 2010-11-10 |
EP2248522A4 (en) | 2013-01-09 |
PT2248522T (pt) | 2017-07-27 |
JP2011511059A (ja) | 2011-04-07 |
AR070323A1 (es) | 2010-03-31 |
MX349358B (es) | 2015-08-25 |
ES2355884A1 (es) | 2011-04-01 |
US20140088135A1 (en) | 2014-03-27 |
PE20091372A1 (es) | 2009-10-18 |
MX2010008327A (es) | 2010-11-30 |
CL2008000374A1 (es) | 2008-04-04 |
BRPI0908072A2 (pt) | 2015-07-21 |
US20110021553A1 (en) | 2011-01-27 |
EP2248522B1 (en) | 2017-05-03 |
CA2714237A1 (en) | 2009-08-13 |
CO6660422A2 (es) | 2013-04-30 |
ES2355884B1 (es) | 2012-01-24 |
WO2009098649A1 (es) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
WO2015120110A3 (en) | Novel pharmaceutical formulations | |
ES2969363T3 (es) | Formulaciones | |
TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
CL2020000747A1 (es) | Formulaciones de niraparib. | |
EA201500431A1 (ru) | Соединения боронатного эфира и его фармацевтические составы | |
CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
WO2017127835A3 (en) | Aqueous formulations and methods of preparation and use thereof | |
EA201290734A1 (ru) | Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
WO2013183062A3 (en) | Palatable formulations of ibuprofen | |
WO2014100351A3 (en) | 8'-hydroxy-dihydroergotamine compounds and compositions | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
DOP2017000307A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
TR201821157T4 (tr) | İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m. | |
CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
AR055562A1 (es) | Derivados 1,3 oxazina y composiciones farmaceuticas que los comprenden. | |
WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
WO2012030914A8 (en) | 4-azolylaminoquinazoline derivatives and methods of use thereof | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
WO2014130691A3 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
EA201791411A1 (ru) | Новая фармацевтическая композиция | |
ECSP10010383A (es) | Polvo para suspension oral de un macrolido inmunosupresor |